Vinapharm to pay 10% cash dividend and plan to list on HoSE

Vinapharm – Vietnam National Pharmaceutical Corporation – held its 2026 annual general meeting of shareholders, announcing the 2025 business results and the 2026–2030 strategic plan. According to the 2025 consolidated financial statements, Vinapharm's pre-tax profit reached VND 825 billion, up 62% from the previous year and 77% above the target. This marked Vinapharm's highest profit to date. From 2021 to 2025, the compound annual growth rate (CAGR) of pre-tax profit was about 37% per year. A milestone in this period was Vinapharm completing its stake increase in Sanofi Vietnam from 15% to 30%. The AGM approved the plan to pay 2025 dividends in cash at 10%. At the meeting, Vinapharm's leadership discussed and clarified many issues of concern to shareholders, including directions for international cooperation, technology transfer, the efficiency of strategic investments, and the roadmap for stock listing. On development orientation, Ms. Han Thi Khanh Vinh – Board member and CEO – said Vinapharm would continue to actively strengthen international cooperation, prioritizing resources for projects with long-term growth potential, with a focus on transferring technology for high-tech drug production in Vietnam. Because the pharmaceutical industry has long investment cycles, especially in production and technology transfer, financial performance typically takes time to manifest. Dr. Nguyen Tri Thuc, Deputy Minister of Health, acknowledged and praised Vinapharm's role in the sector's development, emphasizing the urgent need to raise the sector's self-reliance in the new context. He noted that despite positive results, Vietnam's pharmaceutical sector still faces limitations in technology capability and heavy dependence on imported materials. In this context, technology transfer is not only an opportunity but a necessary requirement to enhance competitiveness and sustainable development. He urged Vinapharm, as the only state-controlled company with controlling interest, to continue leading in technology-transfer programs, especially for originator medicines, vaccines, and biologics, thereby gradually increasing domestic production capacity and ensuring national drug security. The AGM elected the board for the 2026–2031 term. Mr. Nguyen The Ngan was elected Chairman of the Board and Ms. Han Thi Khanh Vinh continued as CEO. With a blend of practical leadership and modern governance, the 2026–2031 board is expected to enable Vinapharm to achieve its strategic goals: to master the technology of producing high-quality medicines, expand and strengthen domestic market share, and position Vietnam as a high-value pharmaceutical production hub in the region. At the close of trading on 23/04, Vinapharm's DVN shares were trading at VND 20,500 per share.